Why ABVC BioPharma Stock Is Up Today
Why ABVC BioPharma Stock Is Up Today
ABVC BioPharma, Inc. (NASDAQ:ABVC) shares are trading higher Tuesday after the company announced it has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company's ophthalmology pipeline.
ABVC BioPharma, Inc.（纳斯达克股票代码：ABVC）周二股价走高，此前该公司宣布已与ForseeCon Eye Corporation就该公司的眼科产品线签订全球许可协议。
The Details:
细节：
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products and clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC BioPharma表示，许可协议包括眼科产品线，包括医疗器械Vitargus许可的产品和临床试验、注册、制造、供应和分销权。
ABVC will receive the first licensing payment of $30 million in cash and shares within 30 days of executing the agreement. ABVC is entitled to another milestone payment of $3.5 million in cash after the first useful fundraise and royalties of 5% of net sales, up to $60 million, after the launch of the licensed product.
ABVC将在协议执行后的30天内收到第一笔3000万美元现金和股票的许可付款。在许可产品推出后，ABVC有权再获得350万澳元现金的里程碑式付款，此前ABVC获得了相当于净销售额5％（最高6000万美元）的特许权使用费。
"We are thrilled to announce a new licensing deal that we believe will make our product available to more patients undergoing the tedious Vitrectomy procedure. This partnership underscores our commitment to providing patients with a better quality of life during and after the procedure," said Dr. Uttam Patil, ABVC's CEO.
“我们很高兴地宣布一项新的许可协议，我们相信这将使更多接受繁琐的玻璃体切除术的患者可以使用我们的产品。这种伙伴关系凸显了我们对在手术期间和手术后为患者提供更好生活质量的承诺。” ABVC首席执行官乌塔姆·帕蒂尔博士说。
Related News: WallStreetBets Is Buzzing About Digital World Stock Ahead Of Trump Media's First Trade Under DJT Ticker
相关新闻：在特朗普媒体根据DJT股票进行首次交易之前，WallstreetBets正在热议数字世界股票
Is ABVC A Good Stock To Buy?
ABVC 是一只值得买入的好股票吗？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like ABVC BioPharma's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投资者在决定股票是否值得买入时可以做出一些决定。除了可以在Benzinga的报价页面（例如ABVC BioPharma的页面）上找到的估值指标和价格走势外，还有一些因素，例如公司是否每季度支付股息或购买大部分股票。
These are known as capital allocation programs. ABVC BioPharma does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
这些被称为资本分配计划。ABVC BioPharma不支付股息，但显然有几种方法可以向股东返还价值。您可以随时在Benzinga的股息日历中搜索下一家即将派发股息的公司，并确定持有该公司股份可以获得什么样的收益率。
For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of ARMOUR Residential REIT by the April 12. Once done, you can expect to receive a nominal payout of $0.24 on April 29.
例如，如果您希望获得14.97％的年化回报率，则需要在4月12日之前购买ARMOUR住宅房地产投资信托基金的股份。完成后，您预计将在4月29日收到0.24美元的名义补助金。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on ABVC BioPharma will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回购计划显然是不同的，而且变化很大。公司可以批准回购计划，并在回购获得批准的时间内酌情购买股票。浏览ABVC BioPharma的最新消息通常可以得出该公司最近是否批准了回购计划。回购计划通常作为股价的支撑，作为需求的支撑。
ABVC Price Action: According to Benzinga Pro, ABVC BioPharma shares are up 20% at $1.26 at the time of publication Tuesday.
ABVC价格走势：根据Benzinga Pro的数据，ABVC BioPharma的股价在周二发布时上涨了20％，至1.26美元。
译文内容由第三方软件翻译。